Polaryx Therapeutics Inc. Common Stock (PLYX)
Stock · NASDAQ · Health Care
$1.93as of 10/16/2026
Price chart
Active signals
Resistance level
$2.06
Industry
Biotechnology: Pharmaceutical Preparations
About PLYX
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical st…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 2
- Website
- polaryx.com/
Fundamentals
- 1-day range
- $1.9$2.03
- Market cap
- $110.66M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-0.11
- Dividend yield
- —
- Beta
- -1.38
- Avg. volume
- 71.4K
52-week range
$1.85$48.91
Forecasts
4 analyst ratings
Buy 90%
Hold 10%
Sell 0%
1-year price forecast
High
$10
+418.1%
Median
$7
+262.7%
Low
$6
+210.9%
Polaryx Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PLYXPolaryx Therapeutics Inc. Common Stock$1.88▼ 3.59%Market cap $110.66MP/E —$1.85$48.91
- NRXPNRX Pharmaceuticals Inc. Common Stock$2.6▼ 4.06%Market cap $111.95MP/E —$1.62$5.06
- CUECue Biopharma Inc. Common Stock$16.71▼ 10.50%Market cap $113.45MP/E —$4.97$45.5
- COYACoya Therapeutics Inc. Common Stock$4.25▼ 2.07%Market cap $107.43MP/E —$3.71$7.75
- CPIXCumberland Pharmaceuticals Inc. Common Stock$7.18▼ 4.77%Market cap $115.07MP/E —$1.85$9.28
- RFLRafael Holdings Inc. Class B Common Stock$1.39▼ 5.44%Market cap $105.04MP/E —$1.12$3.96
- ANIXAnixa Biosciences Inc. Common Stock$2.67▼ 3.96%Market cap $116.70MP/E —$2.32$5.46
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PLYX Polaryx Therapeutics Inc. Common Stock | $110.66M | — | $1.88 | ▼ 3.59% | $1.85$48.91 |
| NRXP NRX Pharmaceuticals Inc. Common Stock | $111.95M | — | $2.6 | ▼ 4.06% | $1.62$5.06 |
| CUE Cue Biopharma Inc. Common Stock | $113.45M | — | $16.71 | ▼ 10.50% | $4.97$45.5 |
| COYA Coya Therapeutics Inc. Common Stock | $107.43M | — | $4.25 | ▼ 2.07% | $3.71$7.75 |
| CPIX Cumberland Pharmaceuticals Inc. Common Stock | $115.07M | — | $7.18 | ▼ 4.77% | $1.85$9.28 |
| RFL Rafael Holdings Inc. Class B Common Stock | $105.04M | — | $1.39 | ▼ 5.44% | $1.12$3.96 |
| ANIX Anixa Biosciences Inc. Common Stock | $116.70M | — | $2.67 | ▼ 3.96% | $2.32$5.46 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →Acquired
88.5K
Disposed
0
- Alex Keun Mo Yang · May 27, 2026 · Buy88.5K @ $4.07
Institutional Ownership
March 31, 2026
- Total shares held
- 2.16M
- Total value held
- $16.30M
- Institutional holders
- 12
Top holders this quarter
- Unknown1.66M
- Unknown170.7K
- Unknown127.5K
- Unknown58.1K
- Unknown41.0K
- Unknown28.0K
- Unknown25.9K
- Unknown13.5K
- Unknown13.5K
- Unknown12.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
PLYX Included in List of 20 Premarket Movers
Polaryx Therapeutics (PLYX) was featured in a Benzinga report listing 20 stocks moving in premarket trading. The article highlights Webuy Global as a primary driver of market movement, with PLYX included in the broader list of active tickers. No specific reasons for PLYX's price action were detailed in the provided summary. The stock currently trades near its 52-week low, with technical indicators showing a support rejection at $2.06.
PLYX Included in List of 20 Premarket Movers. Polaryx Therapeutics (PLYX) was featured in a Benzinga report listing 20 stocks moving in premarket trading. The article highlights Webuy Global as a primary driver of market movement, with PLYX included in the broader list of active tickers. No specific reasons for PLYX's price action were detailed in the provided summary. The stock currently trades near its 52-week low, with technical indicators showing a support rejection at $2.06.